<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN"
        "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
    <PubmedArticle>
        <MedlineCitation Owner="NLM" Status="MEDLINE">
            <PMID Version="1">16172440</PMID>
            <DateCreated>
                <Year>2005</Year>
                <Month>09</Month>
                <Day>20</Day>
            </DateCreated>
            <DateCompleted>
                <Year>2005</Year>
                <Month>09</Month>
                <Day>23</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2007</Year>
                <Month>11</Month>
                <Day>15</Day>
            </DateRevised>
            <Article PubModel="Print">
                <Journal>
                    <ISSN IssnType="Electronic">1539-3704</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>143</Volume>
                        <Issue>6</Issue>
                        <PubDate>
                            <Year>2005</Year>
                            <Month>Sep</Month>
                            <Day>20</Day>
                        </PubDate>
                    </JournalIssue>
                    <Title>Annals of internal medicine</Title>
                    <ISOAbbreviation>Ann. Intern. Med.</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Efficacy and safety of second-generation antidepressants in the treatment of major
                    depressive disorder.
                </ArticleTitle>
                <Pagination>
                    <MedlinePgn>415-26</MedlinePgn>
                </Pagination>
                <Abstract>
                    <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Reviews have compared the efficacy and
                        tolerability of newer second-generation antidepressants with those of placebo or older
                        treatments, but comparative evidence for use of second-generation antidepressants to treat major
                        depressive disorder has not been evaluated.
                    </AbstractText>
                    <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To systematically evaluate comparative data on
                        the efficacy, effectiveness, and tolerability of commonly prescribed second-generation
                        antidepressants (selective serotonin reuptake inhibitors, bupropion, duloxetine, mirtazapine,
                        and venlafaxine) in the treatment of major depressive disorder.
                    </AbstractText>
                    <AbstractText Label="DATA SOURCES" NlmCategory="METHODS">MEDLINE, EMBASE, and PsychLit; the Cochrane
                        Library; and the International Pharmaceutical Abstracts were searched from January 1980 through
                        February 2005 for reviews; randomized, controlled trials; meta-analyses; and observational
                        studies.
                    </AbstractText>
                    <AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">The authors reviewed 46 head-to-head
                        randomized, controlled trials comparing one second-generation antidepressant with another.
                        Twenty-four observational studies and placebo-controlled trials were also included for
                        assessment of safety and tolerability.
                    </AbstractText>
                    <AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Two researchers independently reviewed
                        titles and abstracts. Trained reviewers abstracted data from each study and assigned an initial
                        quality rating. A second reviewer verified the data extraction and quality rating.
                    </AbstractText>
                    <AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">According to fair to good evidence, the
                        second-generation antidepressants that were compared had only minimal differences in efficacy,
                        and 88% of comparative efficacy studies reported no statistically significant difference in any
                        outcome measure at the end of the study. One effectiveness trial rated good and 2 effectiveness
                        trials rated fair reported no statistically significant differences in primary outcome measures
                        for compared drugs. Meta-analyses showed a modest but statistically significant additional
                        treatment effect for sertraline and venlafaxine compared with fluoxetine. About 96% of
                        comparative trials were sponsored by or had at least 1 author affiliated with a pharmaceutical
                        company; the remaining trials did not report funding sources. Adverse event profiles differed
                        among drugs; however, the degree and quality of adverse event assessment varied and only 13% of
                        trials used a standardized scale to assess adverse events.
                    </AbstractText>
                    <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Quantitative analyses could not be done
                        for many drug comparisons because the quantity and quality of the evidence were inadequate. Most
                        published evidence was from trials sponsored by pharmaceutical companies, and publication bias
                        may have occurred.
                    </AbstractText>
                    <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, second-generation
                        antidepressants probably do not differ substantially for treatment of major depressive disorder.
                        Choosing the agent that is most appropriate for a given patient is difficult.
                    </AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Hansen</LastName>
                        <ForeName>Richard A</ForeName>
                        <Initials>RA</Initials>
                        <Affiliation>Division of Pharmaceutical Policy and Evaluative Sciences, University of North
                            Carolina, Chapel Hill, North Carolina 27599, USA. rahansen@unc.edu
                        </Affiliation>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Gartlehner</LastName>
                        <ForeName>Gerald</ForeName>
                        <Initials>G</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Lohr</LastName>
                        <ForeName>Kathleen N</ForeName>
                        <Initials>KN</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Gaynes</LastName>
                        <ForeName>Bradley N</ForeName>
                        <Initials>BN</Initials>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Carey</LastName>
                        <ForeName>Timothy S</ForeName>
                        <Initials>TS</Initials>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <GrantList CompleteYN="Y">
                    <Grant>
                        <GrantID>K23 MH01951-03</GrantID>
                        <Acronym>MH</Acronym>
                        <Agency>NIMH NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                </GrantList>
                <PublicationTypeList>
                    <PublicationType>Comparative Study</PublicationType>
                    <PublicationType>Journal Article</PublicationType>
                    <PublicationType>Meta-Analysis</PublicationType>
                    <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                    <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                    <PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
                    <PublicationType>Review</PublicationType>
                </PublicationTypeList>
            </Article>
            <MedlineJournalInfo>
                <Country>United States</Country>
                <MedlineTA>Ann Intern Med</MedlineTA>
                <NlmUniqueID>0372351</NlmUniqueID>
                <ISSNLinking>0003-4819</ISSNLinking>
            </MedlineJournalInfo>
            <ChemicalList>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance>Antidepressive Agents, Second-Generation</NameOfSubstance>
                </Chemical>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance>Serotonin Uptake Inhibitors</NameOfSubstance>
                </Chemical>
            </ChemicalList>
            <CitationSubset>AIM</CitationSubset>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName>
                    <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
                    <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
                    <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName MajorTopicYN="N">Quality of Life</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
                    <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
                    <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
                </MeshHeading>
            </MeshHeadingList>
            <NumberOfReferences>97</NumberOfReferences>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2005</Year>
                    <Month>9</Month>
                    <Day>21</Day>
                    <Hour>9</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2005</Year>
                    <Month>9</Month>
                    <Day>24</Day>
                    <Hour>9</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2005</Year>
                    <Month>9</Month>
                    <Day>21</Day>
                    <Hour>9</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pii">143/6/415</ArticleId>
                <ArticleId IdType="pubmed">16172440</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>

</PubmedArticleSet>
